LSD1 inhibition attenuates targeted therapy-induced lineage plasticity in BRAF mutant colorectal cancer
Abstract Background BRAF activating mutations occur in approximately 10% of metastatic colorectal cancer (CRCs) and are associated with worse prognosis in part due to an inferior response to standard chemotherapy. Standard of care for patients with refractory metastatic BRAF V600E CRC is treatment w...
Saved in:
| Main Authors: | Christopher A. Ladaika, Averi Chakraborty, Ashiq Masood, Galen Hostetter, Joo Mi Yi, Heather M. O’Hagan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12943-025-02311-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
BRAF V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab
by: Toru Imai, et al.
Published: (2024-12-01) -
Second-generation BRAF inhibitor Encorafenib resistance is regulated by NCOA4-mediated iron trafficking in the drug-resistant malignant melanoma cells
by: Ceyda Colakoglu Bergel, et al.
Published: (2025-01-01) -
Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable <i>BRAF</i> V600-mutated metastatic melanoma in Russia
by: N. A. Avxentyev, et al.
Published: (2023-11-01) -
Comparative effectiveness among BRAF plus MEK inhibitors for patients with BRAF V600-mutant melanoma☆
by: G.K. In, et al.
Published: (2024-12-01) -
LSD1+8a is an RNA biomarker of neuroendocrine prostate cancer
by: Anbarasu Kumaraswamy, et al.
Published: (2025-05-01)